Please sign in to follow a disease.
New drug ATTO-1091 put to the test for safety in ulcerative colitis
NCT ID NCT07819799
First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time
Summary
Researchers are running a phase 1 trial to find out how safe and tolerable ATTO-1091 is in healthy adults and in people with ulcerative colitis. The study also measures how long the drug stays in the body. About 96 participants will receive either ATTO-1091 or a placebo, visit the clinic for checkups, and keep a diary of symptoms. The main goal is to track medical problems and laboratory changes, not to see if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ATTO-1091, an experimental drug given as an injection or infusion
- What this could lead to
- If ATTO-1091 proves safe and stays in the body as intended, it could become a new treatment option for ulcerative colitis.
- What could go wrong
- This is a first-in-human phase 1 trial with about 96 participants, so most drugs at this stage fail or cause unexpected side effects. The trial does not test whether the drug actually treats ulcerative colitis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 96 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria: * Any sex or gender who is 18 to 60 years old, inclusive, at Screening. * Body weight of 45 to 125 kg, inclusive, and body mass index (BMI) between 18.5 and 35 kg/m2. * Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs. * Meets contraception requirements * Negative pregnancy test for participants of childbearing potential. Part 3 (Participants with Ulcerative Colitis) Key Inclusion Criteria: * Any sex or gender who is 18 to 80 years old * Body weight of 45 to 125 kg and BMI between 17.0 and 40.0 kg/m2 * UC diagnosis confirmed by endoscopy and histology ≥3 months prior to Screening * Moderately to severely active UC as defined by Modified Mayo Clinic Score (stool frequency, rectal bleeding, endoscopy) 5 to 9 inclusive, with Mayo endoscopic subscore ≥2 as confirmed by the central reader during Screening * Rectal bleeding subscore ≥1 and stool frequency subscore ≥1 at Screening. * Naïve to treatment with advanced therapies or has had an inadequate response, loss of response, or intolerance to no more than 3 drugs in 2 classes of the following: * Tumor necrosis factor (TNF-α) antagonists * Interleukin IL-12/IL-23 antagonists * Integrin inhibitors * JAK antagonists * S1P receptor agonists * Novel class with biologic-like activity (e.g. TL1A antagonists) * Meets washout criteria for prior UC therapies as specified in the protocol. * Negative pregnancy test for participants of childbearing potential Parts 1\&2 (Healthy Volunteers) Key Exclusion Criteria * Any clinically significant underlying illness * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of uncontrolled asthma requiring systemic corticosteroids or hospitalization for asthma within 6 months prior to Day 1 * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV * Active or latent tuberculosis infection * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent to approximately 40 mg nicotine) per day * History of drug or alcohol abuse * Laboratory values outside of the normal range considered clinically significant by the investigator Part 3 (Participants with Ulcerative Colitis) Key Exclusion Criteria: * Any clinically significant underlying illness * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of uncontrolled asthma requiring systemic corticosteroids or hospitalization for asthma within 6 months prior to Day 1 * History of known primary immunodeficiency or is considered immunocompromised * Has been treated for a parasitic infection in the past 6 months * Participant has active HBV or HCV or is positive for HIV * Participant has active or latent TB * Stool positive for Clostridioides difficile toxin at Screening * Concomitant primary sclerosing cholangitis. * History of active major depressive episode or suicidal ideation * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients * Diagnosis of non-UC or confounding GI conditions including Crohn's disease, indeterminate colitis, microscopic colitis, ischemic or radiation colitis. * Disease limited to isolated ulcerative proctitis (\<15 cm). * Unresected colonic dysplasia or unresected adenomatous colonic polyps, fulminant colitis, toxic megacolon, bowel perforation, current colonic strictures, fistulae, stoma, ileostomy, colostomy, abdominal abscess, or anticipated need for colectomy during the study. * History of extensive colonic resection * History of drug or alcohol abuse * Laboratory values outside of the normal range considered clinically significant by the investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ulcerative colitis (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Triple-Pronged attack on gut inflammation put to the test
- Two biologics go head to head in ulcerative colitis
- Antiparasitic drug tested as new weapon against ulcerative colitis
- Could your Donor's gut bacteria decide whether a stool transplant works?
- Exercise as a potential remedy for IBD-related fatigue